Takeda and Schrodinger announce new research collaboration

Takeda has announced a new drug research collaboration with Schrodinger, a drug discovery firm that utilises advanced computational methods.

The multi-target research collaboration will focus on diseases that align with Takeda's core therapeutic areas of interest and will take advantage of Schrodinger's in silico platform-driven drug discovery capabilities.

Schrodinger will lead the multi-target discovery effort, with Takeda providing protein crystal structures to help its partner use its computational platform to guide the design of new chemical entities. Takeda will also contribute deep therapeutic area knowledge and expertise in structural biology.

Under the terms of the deal, Takeda will have the option to exclusively license any successful programmes from Schrodinger, with milestone fees of up to $170 million (130.6 million pounds) per programme having been agreed.

Dr Stephen Hitchcock, head of research for Takeda, said: "Takeda's business model is focused on creating mutually beneficial partnerships that capitalise on the complementary capabilities of both parties in order to accelerate the discovery of new therapies for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.